[go: up one dir, main page]

WO1996011266A3 - Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci - Google Patents

Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci Download PDF

Info

Publication number
WO1996011266A3
WO1996011266A3 PCT/US1995/012770 US9512770W WO9611266A3 WO 1996011266 A3 WO1996011266 A3 WO 1996011266A3 US 9512770 W US9512770 W US 9512770W WO 9611266 A3 WO9611266 A3 WO 9611266A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
cell proliferation
smooth muscle
muscle cell
inhibiting smooth
Prior art date
Application number
PCT/US1995/012770
Other languages
English (en)
Other versions
WO1996011266A2 (fr
Inventor
Teresa L Burgess
Catherine L Farrell
Eric F Fisher
Original Assignee
Amgen Inc
Teresa L Burgess
Catherine L Farrell
Eric F Fisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Teresa L Burgess, Catherine L Farrell, Eric F Fisher filed Critical Amgen Inc
Priority to AU38895/95A priority Critical patent/AU3889595A/en
Publication of WO1996011266A2 publication Critical patent/WO1996011266A2/fr
Publication of WO1996011266A3 publication Critical patent/WO1996011266A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des oligonucléotides multi-G capables d'inhiber la prolifération de cellules musculaires lisses. Les oligonucléotides multi-G de l'invention peuvent être utilisés en tant que composés thérapeutiques d'acides nucléiques afin d'inhiber la prolifération de cellules musculaires lisses dans des artères ex vivo, et plus particulièrement contre la resténose. L'invention concerne également des compositions pharmaceutiques contenant les oligonucléotides multi-G. En outre, l'invention concerne un procédé de triage d'oligonucléotides en fonction de leur aptitude à inhiber la prolifération de cellules musculaires lisses ex vivo.
PCT/US1995/012770 1994-10-05 1995-10-03 Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci WO1996011266A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38895/95A AU3889595A (en) 1994-10-05 1995-10-03 Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31845894A 1994-10-05 1994-10-05
US08/318,458 1994-10-05

Publications (2)

Publication Number Publication Date
WO1996011266A2 WO1996011266A2 (fr) 1996-04-18
WO1996011266A3 true WO1996011266A3 (fr) 1996-12-12

Family

ID=23238272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012770 WO1996011266A2 (fr) 1994-10-05 1995-10-03 Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci

Country Status (2)

Country Link
AU (1) AU3889595A (fr)
WO (1) WO1996011266A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2324503T3 (es) 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
WO2001023550A2 (fr) 1999-09-29 2001-04-05 Diagnocure Inc. Variantes l'arnm du pca3 dans les tissus benins et malins de la prostate
ES2427853T3 (es) 2003-02-07 2013-11-04 Diagnocure Inc. Procedimiento para detectar cáncer de próstata en una muestra
CA2491067A1 (fr) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Rapport entre arnm dans les sediments urinaires ou l'urine en tant que marqueur pronostique du cancer de la prostate
EP4223299A3 (fr) 2007-12-04 2023-08-30 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
JP5749494B2 (ja) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
EP3238738B1 (fr) 2008-11-10 2020-09-23 Arbutus Biopharma Corporation Nouveaux lipides et compositions d'administration d'agents thérapeutiques
NZ596958A (en) 2009-06-10 2014-04-30 Tekmira Pharmaceuticals Corp Improved lipid formulation
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
CA2783372C (fr) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions utilisees pour l'administration d'acides nucleiques
ES2749426T3 (es) 2009-12-18 2020-03-20 Univ British Columbia Métodos y composiciones para administración de ácidos nucleicos
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016188A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour l'administration d'agents actifs
AU2012207606B2 (en) 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP2760477B1 (fr) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Lipides di-aliphatiques pegylés substitués
BR112014020824B1 (pt) 2012-02-24 2022-10-04 Protiva Biotherapeutics Inc Lipídeo, partícula de lipídeo e composição farmacêutica
AU2014287002A1 (en) 2013-07-11 2016-02-11 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
JP7709981B2 (ja) 2020-03-17 2025-07-17 ジェネヴァント サイエンシズ ゲーエムベーハー 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
CN117479963A (zh) 2020-12-18 2024-01-30 盖纳万科学有限公司 Peg脂质和脂质纳米粒子
US20250243244A1 (en) 2021-03-31 2025-07-31 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
WO2022240721A1 (fr) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions et méthodes de modulation de l'activité du facteur 5 de régulation de l'interféron (irf-5)
MX2023013352A (es) 2021-05-10 2024-01-31 Entrada Therapeutics Inc Composiciones y métodos para terapéuticos intracelulares.
MX2023015509A (es) 2021-06-23 2024-01-22 Entrada Therapeutics Inc Compuestos antisentido y metodos para dirigirse a repeticiones cug.
WO2023014938A1 (fr) 2021-08-05 2023-02-09 Sanegene Bio Usa Inc. Dérivés de ribose modifiés par 1'-alkyle et procédés d'utilisation
CN118076619A (zh) 2021-09-22 2024-05-24 美国圣因生物股份有限公司 用于寡核苷酸的体内递送的2′-烷基或3′-烷基修饰的核糖衍生物
CN118076621A (zh) 2021-10-05 2024-05-24 美国圣因生物股份有限公司 多羟基化的环戊烷衍生物及使用方法
JP2025504682A (ja) 2022-01-31 2025-02-14 ジェネバント サイエンシズ ゲーエムベーハー ポリ（アルキルオキサゾリン）－脂質コンジュゲートおよびそれを含む脂質粒子
EP4574172A3 (fr) 2022-01-31 2025-10-01 Genevant Sciences Gmbh Lipides cationiques ionisables pour nanoparticules lipidiques
US20230346819A1 (en) 2022-02-22 2023-11-02 Sanegene Bio Usa Inc. 5'-modified carbocyclic ribonucleotide derivatives and methods of use
KR20250034973A (ko) 2022-07-11 2025-03-11 사네진 바이오 유에스에이 인크. 최적화된 2'-변형된 리보스 유도체 및 사용 방법
WO2024229397A1 (fr) 2023-05-03 2024-11-07 Sanegene Bio Usa Inc. Conjugués à base de lipides pour système nerveux central systémique, système nerveux périphérique et administration oculaire
WO2025024523A1 (fr) 2023-07-24 2025-01-30 Sanegene Bio Usa Inc. Agent d'amélioration à base de lipides pour l'administration d'arn et une thérapie à arn
WO2025052278A1 (fr) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Lipides cationiques à base de pyrrolidine pour administration de nanoparticules lipidiques d'agents thérapeutiques à des cellules stellaires hépatiques
WO2025133951A1 (fr) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Lipides ionisables appropriés pour des nanoparticules lipidiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
WO1994008053A1 (fr) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides possedant une sequence noyau g4 conservee

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
WO1994008053A1 (fr) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides possedant une sequence noyau g4 conservee

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGESS, T. ET AL.: "The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 9, 25 April 1995 (1995-04-25), WASHINGTON US, pages 4051 - 4055, XP002015216 *
ECKER, D. ET AL.: "Rational screening of oligonucleotide combinatorial libraries for drug discovery", NUCLEIC ACIDS RESEARCH, vol. 21, no. 8, 25 April 1993 (1993-04-25), OXFORD GB, pages 1853 - 1856, XP002015215 *
FARRELL, C. ET AL.: "The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 5, 1995, US, pages 175 - 183, XP002015217 *
YASWEN, P. ET AL.: "Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 3, no. 1, 1993, US, pages 67 - 77, XP002015214 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Also Published As

Publication number Publication date
AU3889595A (en) 1996-05-02
WO1996011266A2 (fr) 1996-04-18

Similar Documents

Publication Publication Date Title
WO1996011266A3 (fr) Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci
IL109579A0 (en) Bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
HUP0200804A3 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
BR9808109A (pt) Inibidor terapêutico de células vasculares da musculatura lisa
HUP0002037A3 (en) Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds
CA2359510A1 (fr) Diphenylurees a substituants .omega.-carboxyaryles, inhibitrices de kinase raf
HUP0301101A3 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
HUP0102477A3 (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds
HU9502587D0 (en) Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
WO1993021942A3 (fr) Utilisation d'inhibiteurs de metalloprotease matricielle (mmp)
CA2268394A1 (fr) Nouveaux derives de pyrazol heterocyclylmethyle-substitues
EP1420009A3 (fr) Nouveaux dérivés d'acides amines présentant une meilleure activité contre la résistance à plusieurs médicaments
NZ333373A (en) Use of amino acid derivatives for preparing compositions with improved multi-drug resistance activity
HUP0203376A3 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them and their use
IL114586A (en) Droloxifene for use in the treatment of cardiovascular diseases and pharmaceutical compositions comprising same
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
HUP0000678A3 (en) Aminobenzophenones as inhibitors of interleukin and tnf, process for their preparation and pharmaceutical compositions containing the same
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0002921A3 (en) Cyanoguanidines as cell proliferation inhibitors, process for producing them and pharmaceutical compositions containing them
GB9804025D0 (en) Orthomolecular medical use of L-citrulline for vasprotection,relaxative smooth muscle tone and cell protection
TJ347B (en) Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia
HUP9900071A3 (en) Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase